Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial

Overview of attention for article published in Arthritis Research & Therapy, September 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

policy: 1 policy source

twitter: 6 X users

Citations

dimensions_citation: 58 Dimensions

Readers on

mendeley: 84 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Sarilumab

Cited by Canadian Agency for Drugs and Technologies in Health on 02 May 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.